There are several explanations for the growing number of nearsightedness people.Time spent looking at computer and cellphone screens has been identified as a culprit.
A growing proportion of people are nearsighted or, to use the medical term, myopic.In the U.S., in the early ’70s, roughly a quarter of the population was myopic. Now is about a third. The increasing proportion of “myopes” is a global phenomenon. According to some projections, by the mid-century, more than half of the world’s population will be nearsighted. Of course, many people with myopia manage just fine with glasses or contact lenses, but there are some more serious aspects to the trend. For one thing, myopia is associated with a greater risk of cataracts, retinal detachment and glaucoma. And a certain proportion — the estimates vary quite a bit — of myopia cases are serious, or “pathological,” and can lead to loss of vision
Researchers have come up with a number of explanations for the growing number of nearsightedness people. Not surprisingly, time spent looking at computer and cellphone screens has been identified as a possible culprit. There is also a theory that nearsightedness is associated with lack of time spent outdoors. Results from a randomized trial published in 2018 showed differences in the eyes of children who were encouraged to spend more time outdoors that would positively affect myopia.
Researchers are looking for other ways to lessen myopia, which is caused by the shape of the eye and, more specifically, when the eye takes on an oval shape and grows too long from the front to back. Some of the interventions that have been tested include atropine drops (the thinking is that they affect the scleral tissue — the white of the eye — and therefore retard the lengthening) and wearing special contact lenses at night to flatten the cornea (orthokeratology).
Another approach are multifocal contact lenses, which focus some light on the retina to improve distance vision and some in front of the retina, which some evidence suggests would affect the elongation of the eye.
According to the National Eye Institute (NEI), which is one of the institutes of the National Institutes of Health, multifocal contact lenses have been used on an off-label basis for years to slow the progression of myopia. Meanwhile, though, the NEI has been funding the BLINK (Bifocal Lenses in Nearsighted Kids) study to test multifocal lenses in a randomized trial and build up the evidence base for whether they work or don’t work.
The BLINK researchers enrolled 294 children, ages 7 to 11, at two optometry schools in Columbus, Ohio, and Houston. They were randomized into three groups of an equal number (98) children. Children in one group wore single-vision contact lenses, children in another group wore “medium add power” versions of the multifocal lenses and a children in the third group wore high add power lenses. The primary outcome was a standard measurement of the worsening of myopia after three years.
Results of the BLINK study were published earlier this month in JAMA, and most suggest that multifocal lenses do, in fact, work to reduce myopia.
The high power add versions of the lenses were more effective than the medium power at slowing down myopia, and the medium ones were more effective than the single-vison lenses. The lenses stacked up the same way when the researchers measured the shape of the eye in the dimension that affects myopia.
“Multifocal contact lenses slow myopia progression in children” was the unequivocal headline on the NEI press release about the results. The press release quotes the BLINK study chair, Jeffrey J. Walline, O.D., Ph.D., as saying that it is “especially good news to know that children as young as seven achieved optimal visual acuity and got used to wearing multifocal lenses much the way they would a single version contact lens.” Walline is the associate dean for research at Ohio State University College of Optometry.
However, the accompanying editorial by Neil M. Bressler, M.D., of Johns Hopkins University, suggested interpreting the BLINK results with caution. Bressler said the clinical difference in the myopia reduction between high power lenses and the single-vision lenses was unclear. He also said that prevention of myopia may be less relevant than prevention of pathological prevention. In addition, Bressler noted that outcomes measured after three years couldn’t show whether the effect of the lenses will last into adulthood.
Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint
December 7th 2023A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Positive Long-term Results Seen with Vabysmo in Retinal Vein Occlusion
October 10th 2023The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More